Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 7, 2010, Pages 722-729

  Horiuchi, Yuki ^a   Hirayama, Satoshi ^a   Soda, Satoshi ^b   Seino, Utako ^c   Kon, Mika ^a   Ueno, Tsuyoshi ^a   Idei, Mayumi ^a   Hanyu, Osamu ^d   Tsuda, Takashi ^e   Ohmura, Hirotoshi ^a   Miida, Takashi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIIGATA CITY GENERAL HOSPITAL   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^d NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^e Kido Hospital   (Japan)

Author keywords

Hs CRP; Inflammation; Pleiotropic effect; SAA; Statin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; SERUM AMYLOID A; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ECHOGRAPHY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY;

EID: 77955806939     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.3632     Document Type: Article

References (22)

1. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 1986; 256: 2835-2838
2. Multiple Risk Factor Intervention Trial Research Group: Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA, 1982; 248: 1465-1477
3. Miida T, Hirayama S, Nakamura Y: Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb, 2004; 11: 253-264
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The West of Scotland Coronary Prevention Study Group. N Eng l J Med,1995; 333: 1301-1307
5. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet, 2006; 368: 1155-1163
6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389
7. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002; 360: 7-22
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-1009
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339: 1349-1357
10. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126
11. Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation, 2002; 105: 1135-1143
12. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 2001; 103: 1813-1818
13. Ridker PM, Rifai N, Rose L, Burning JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 2002; 347: 1557-1565
14. Meek RL, Urieli-Shoval S, Benditt EP: Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. PNAS, 1994; 91: 3186-3190.
15. Liao JK: Clinical implications for statin pleiotropy. Curr Opin Lipidol, 2005; 16: 624-629
16. Miida T, Takahashi A, Ikeuchi T: Prevention of stroke and dementia by statin therapy: Experimental and clinical evidence of their pleiotropic effects, Pharmacology & Therapeutics, 2007; 113: 378-393
17. Hata Y, Mabuchi H, Saito Y, Itakura H, Egusa G, Ito H, Teramoto T, Tsushima M, Tada N, Oikawa S, Yamada N, Yamashita S, Sakuma N, Sasaki J; Working committee on JAS guideline for diagnosis and treatment of hyperlipidemias: Report of the Japan Atherosclerosis Society (JAS) guideline for diagnosis and treatment of hyperlipidemia in Japanese adults. J Atheroscler Thromb, 2002; 9: 1-27
18. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998; 98: 839-844
19. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med, 2008; 359: 2195-2207
20. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T: Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood, 2004; 103: 4188-4194
21. Sato H, Miida T, Wada Y, Mruyama M, Murakami S, Hasegawa H, Kuroda T, Narita I, Gejyo F: Atherosclerosis is accelerated in well-controlled Systemic Lupus Erythematosus (SLE) even in the premenopausal state, and further exaggerated in the postmenopausal state. Clin Chim Acta, 2007; 385: 35-42
22. Miida T, Seino U, Miyazaki O, Hanyu O, Hirayama S, Saito T, Ishikawa Y, Akamatsu S, Nakano T, Nakajima K, Okazaki M, Okada M: Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis, 2008; 200: 329-335